Aggressive and complex surgery for advanced ovarian cancer: An economic analysis

Gynecologic Oncology

Volumn 112, Issue 1, 2009, Pages 16-21

  Aletti, Giovanni D ^a   Podratz, Karl C ^a   Moriarty, James P ^a   Cliby, William A ^a   Long, Kirsten Hall ^a  

^a MAYO CLINIC   (United States)

Author keywords

Aggressive surgery; Cost effectiveness; Economic analysis; Ovarian cancer

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOREDUCTIVE SURGERY; ECONOMIC ASPECT; FEMALE; HOSPITAL COST; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; QUALITY OF LIFE;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; COST-BENEFIT ANALYSIS; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HEALTH CARE COSTS; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS;

EID: 57649097134     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.10.008     Document Type: Article

References (33)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA: Cancer J. Clin. 58 2 (2008) 71-96
2. Announcements: FIGO stages-1988 revision. Gynecol. Oncol. 35 (1989) 125-126
3. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., and Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 20 (2002) 1248-1259
4. Winter III W.E., Maxwell G.L., Tian C., Carlson J.W., Ozols R.F., Rose P.G., et al. Gynecologic Oncology Group Study. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 25 24 (2007) 3621-3627
5. Winter III W.E., Maxwell G.L., Tian C., Sundborg M.J., Rose G.S., Rose P.G., et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 26 1 (2008) 83-89
6. Chi D.S., Eisenhauer E.L., Lang J., Huh J., Haddad L., Abu-Rustum N.R., et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?. Gynecol. Oncol. 103 2 (2006) 559-564
7. Aletti G.D., Podratz K.C., Jones M.B., and Cliby W.A. Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. J. Am. Coll. Surg. 203 (2006) 521-526
8. Eisenkop S.M., and Spirtos N.M. Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with "biological aggressiveness" and survival?. Gynecol. Oncol. 82 (2001) 435-441
9. Aletti G.D., Dowdy S.C., Podratz K.C., and Cliby W.A. Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecol. Oncol. 100 (2006) 283-287
10. Eisenhauer E.L., Abu-Rustum N.R., Sonoda Y., Levine D.A., Poynor E.A., Aghajanian C., et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol. Oncol. 103 3 (2006) 1083-1090
11. Montz F.J., Schlaerth J.B., and Berek J.S. Resection of diaphragmatic peritoneum and muscle: role in cytoreductive surgery for ovarian cancer. Gynecol. Oncol. 35 (1989) 338-340
12. Jaeger W., Ackermann S., Kessler H., Katalinic A., and Lang N. The effect of bowel resection on survival in advanced epithelial ovarian cancer. Gynecol. Oncol. 83 (2001) 286-291
13. Bristow R.E., del Carmen M.G., Kaufman H.S., and Montz F.J. Radical oophorectomy with primary stapled colorectal anastomosis for resection of locally advanced epithelial ovarian cancer. J. Am. Coll. Surg. 197 (2003) 565-574
14. Magtibay P.M., Adams P.B., Silverman M.B., Cha S.S., and Podratz K.C. Splenectomy as part of cytoreductive surgery in ovarian cancer. Gynecol. Oncol. 102 2 (2006) 369-374
15. Eisenkop S.M., Spirtos N.M., and Lin W.C. Splenectomy in the context of primary cytoreductive operations for advanced epithelial ovarian cancer. Gynecol. Oncol. 100 2 (2006) 344-348
16. Merideth M.A., Cliby W.A., Keeney G.L., Lesnick T.G., Nagorney D.M., and Podratz K.C. Hepatic resection for metachronous metastases from ovarian carcinoma. Gynecol. Oncol. 89 (2003) 16-21
17. Aletti G., Dowdy S.C., Gostout B.S., Jones M.B., Stanhope C.R., Wilson T.O., et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet. Gynecol. 107 (2006) 77-85
18. Aletti G.D., Dowdy S.C., Podratz K.C., and Cliby W.A. Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. Am. J. Obstet. Gynecol. 197 6 (2007) 676.e1-676.e7
19. Aletti G.D., Santillan A., Eisenhauer E.L., Hu J., Aletti G., Podratz K.C., et al. A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecol. Oncol. 107 1 (2007) 99-106
20. Lubsen J., Hoes A., and Grobbee D. Implications of trial results: the potentially misleading notions of number needed to treat and average duration of life gained. Lancet 356 (2000) 1757-1759
21. Mark D.B., Nelson C.L., Anstrom K.J., Al-Khatib S.M., Tsiatis A.A., Cowper P.A., et al. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the sudden cardiac death in heart failure trial (SCD-HeFT). Circulation 114 (2006) 135-142
22. In: Drummond M.F., Sculpher M.J., Torrance G.W., O'Brien B.J., and Stoddart G.L. (Eds). Methods for the economic evaluation of health care programmes. 3rd ed. (2005), Oxford University Press
23. Efron B., and Tibshirani R. An introduction to the bootstrap (1998), Chapman & Hall/CRC, Boca Raton, FL
24. Glick H.A., Doshi J.A., Sonnad S.S., and Polsky D. Economic evaluation in clinical trials (2007), Oxford University Press, Oxford, England
25. Junor E.J., Hole D.J., McNulty L., Mason M., and Young J. Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. Br. J. Obstet. Gynaecol. 106 (1999) 1130-1136
26. Tingulstad S., Skjeldestad F.E., and Hagen B. The effect of centralization of primary surgery on survival in ovarian cancer patients. Obstet. Gynecol. 102 (2003) 499-505
27. Engelen M.J., Kos H.E., Willemse P.H.B., Aalders J.G., de Vries E.G., Schaapveld M., et al. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer 106 (2006) 589-598
28. Chan J.K., Kapp D.S., Shin J.Y., Husain A., Teng N.N., Berek J.S., et al. Influence of the gynecologic oncologist on the survival of ovarian cancer patients. Obstet. Gynecol. 109 6 (2007) 1342-1350
29. Chi D.S., Franklin C.C., Levine D.A., Akselrod F., Sabbatini P., Jarnagin W.R., et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol. Oncol. 94 (2004) 650-654
30. Neumann P.J. Using cost-effectiveness analysis to improve health care: opportunities and barriers (2005), Oxford University Press, Oxford 157-158
31. Devlin N., and Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Economics 13 5 (2004) 437-452
32. Bristow R.E., Santillan A., Diaz-Montes T.P., Gardner G.J., Giuntoli II R.L., Meisner B.C., et al. Centralization of care for patients with advanced-stage ovarian cancer: a cost-effectiveness analysis. Cancer 109 8 (2007) 1513-1522
33. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354 (2006) 34-43